Characteristics of the 416 patients
| Sex ratio, M/F, no. | 225/191 |
| Median age (range), y | 72 (65-85) |
| Performance status, no. patients | |
| 0 | 109 |
| 1 | 193 |
| 2 | 102 |
| 3 | 12 |
| Median WBC count (range), × 109/L | 5.3 (0.1-420) |
| AML morphology, no. patients | |
| de novo AML | 353 |
| RAEB-T | 26 |
| FAB-M1/2 | 173 |
| FAB-M4/5 | 112 |
| FAB-M0/6/7 | 122 |
| Unclassified | 20 |
| post-MDS AML | 63 |
| RAEB-T | 16 |
| Other | 47 |
| Karyotype, no. patients | |
| Not done | 27 |
| Failure | 50 |
| High risk | 49 |
| Monosomy 7 | 7 |
| Abnormalities of chromosome 5 and 7 | 6 |
| 3q26 abnormalities | 4 |
| Complex, 5 abnormalities or more | 32 |
| Standard risk | 290 |
| t(8;21) | 6 |
| inv(16)/t(16;16) | 6 |
| Normal | 168 |
| Isolated trisomy 8 | 17 |
| del(5q) | 13 |
| del(7q) | 9 |
| 11q23 abnormalities | 6 |
| Complex, 3 or 4 abnormalities | 8 |
| Other various abnormalities | 57 |
| Sex ratio, M/F, no. | 225/191 |
| Median age (range), y | 72 (65-85) |
| Performance status, no. patients | |
| 0 | 109 |
| 1 | 193 |
| 2 | 102 |
| 3 | 12 |
| Median WBC count (range), × 109/L | 5.3 (0.1-420) |
| AML morphology, no. patients | |
| de novo AML | 353 |
| RAEB-T | 26 |
| FAB-M1/2 | 173 |
| FAB-M4/5 | 112 |
| FAB-M0/6/7 | 122 |
| Unclassified | 20 |
| post-MDS AML | 63 |
| RAEB-T | 16 |
| Other | 47 |
| Karyotype, no. patients | |
| Not done | 27 |
| Failure | 50 |
| High risk | 49 |
| Monosomy 7 | 7 |
| Abnormalities of chromosome 5 and 7 | 6 |
| 3q26 abnormalities | 4 |
| Complex, 5 abnormalities or more | 32 |
| Standard risk | 290 |
| t(8;21) | 6 |
| inv(16)/t(16;16) | 6 |
| Normal | 168 |
| Isolated trisomy 8 | 17 |
| del(5q) | 13 |
| del(7q) | 9 |
| 11q23 abnormalities | 6 |
| Complex, 3 or 4 abnormalities | 8 |
| Other various abnormalities | 57 |
WBC indicates white blood cell count; FAB, French-American-British classification; RAEB-T, refractory anemia with excess of blast in transformation.